PUBLISHER: Acute Market Reports | PRODUCT CODE: 1560986
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1560986
Asthma Biologics Market - Growth, Future Prospects and Competitive Analysis, 2024 - 2032
The asthma biologics market is focused on the development and sale of biological products or 'biologics' that aid in treating and managing asthma, a chronic respiratory ailment. These biologics are manufactured from a variety of natural sources and employ a range of methods to control asthma, primarily targeting and neutralizing specific cells or proteins that cause inflammation and constriction of airways. The asthma biologics market is estimated to grow at a CAGR of 12.4% from 2024 to 2032.
Asthma Biologics Market Dynamics
Driver: Rising Prevalence of Severe Asthma Cases
One of the primary drivers propelling the asthma biologics market's growth is the escalating number of severe asthma cases worldwide. Asthma, as a condition, has transitioned from being merely a widespread concern to a severe health crisis for a substantial percentage of patients. According to healthcare reports, a significant chunk of asthma patients does not achieve symptom control with standard treatments, paving the way for biologics as an effective solution. Furthermore, urbanization and the accompanied pollution have been directly correlated with rising asthma cases, amplifying the need for advanced treatments such as biologics.
Opportunity: Personalized Biologics for Asthma
An emerging opportunity in this market segment is the development of personalized biologics for asthma treatment. Each asthma patient's response to biologics can vary, and a one-size-fits-all approach might not yield optimal results for everyone. Recognizing this, pharmaceutical companies are delving into creating patient-specific biologic treatments. By studying individual patient profiles, including genetic markers and specific asthma triggers, these personalized biologics promise higher efficacy and fewer side effects.
Restraint: High Treatment Costs
While biologics promise improved outcomes for asthma patients, their high costs can't be ignored. Producing biologics is an intricate process requiring sophisticated technology and extensive research, which inevitably escalates the treatment costs. These elevated prices make biologics inaccessible to a considerable segment of asthma patients, especially in developing and underdeveloped nations, where patients either can't afford these treatments or don't have access to health insurance that would cover such expenses.
Challenge: Ensuring Consistent Efficacy
Another pressing challenge in the asthma biologics market is ensuring consistent efficacy across diverse patient groups. Biologics, due to their nature, sometimes show varying degrees of effectiveness in different demographic groups. Factors like genetic variability, presence of comorbid conditions, or even variations in disease pathology can impact the drug's efficacy. This inconsistency poses a challenge, as pharmaceutical companies need to guarantee that their products are not just effective but consistently so, across different patient populations.
Market Segmentation by Drug Class
Selective Immuno-suppressants: These drugs garnered the highest revenue in 2023, attributable to their proven efficacy in curbing the immune system's exaggerated response without compromising overall immune function. Their targeted approach, which primarily suppresses the inflammatory process involved in asthma, made them a preferred choice among healthcare professionals. A robust sales infrastructure backed by substantial medical endorsements further contributed to their market prominence. While the revenue for interleukin inhibitors trailed behind immuno-suppressants, they boasted the Highest Compound Annual Growth Rate (CAGR). The reason is their cutting-edge mechanism of action. These inhibitors target specific interleukins, proteins responsible for the inflammatory response in asthma, reducing the frequency and severity of asthma exacerbations. Their growing popularity is anchored in their potential to treat patients unresponsive to conventional therapies. Other drug classes, including monoclonal antibodies and bronchodilators, secured a significant market share but didn't overshadow the dominance of the aforementioned categories. Their consistent performance and diverse applications, however, ensure they remain integral to the asthma biologics landscape.
Market Segmentation by Distribution Channel
Traditional retail pharmacies held the largest revenue chunk in 2023. Their accessibility, the trust patients place in them, coupled with the benefit of immediate possession of medicines, underpinned their dominance. The distribution channel expected to manifest the highest CAGR from 2024 to 2032 is E-commerce. This shift towards online pharmacies is propelled by factors such as convenience, the breadth of options, and sometimes, cost-effectiveness. As digital health initiatives gain traction, and as the world becomes increasingly interconnected online, this segment's growth seems almost inevitable. Other channels, including hospital pharmacies and specialty drug stores, contributed sizably to the distribution matrix, capitalizing on their niche clientele and specialized services.
Market Segmentation by Region
In terms of geographical distribution, North America, particularly the U.S., led in revenue percentages in 2023. The region's advanced healthcare infrastructure, coupled with heightened awareness and accessibility to advanced asthma treatments, drove its market leadership. However, Asia-Pacific is anticipated to showcase the highest CAGR from 2024 to 2032. This surge is ascribed to increasing healthcare investments, a burgeoning middle-class demographic demanding quality healthcare, and escalating asthma prevalence in countries like India and China.
Competitive Trends
The asthma biologics market's competitive realm is marked by robust R&D initiatives, strategic mergers, and acquisitions, and an unyielding focus on innovation. In 2023, top players such as Amgen, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., GSK plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. solidified their market positions through a blend of novel product launches and global expansion strategies. These companies have been investing heavily in research to unearth novel drug formulations with higher efficacies. Collaborative efforts, both in terms of research partnerships and distribution alliances, emerged as a key strategy to penetrate untapped markets and diversify product portfolios.
Historical & Forecast Period
This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Asthma Biologics market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users & consumption volume, price, and value.
Geographical revenues generated by countries considered in the report
Micro and macro environment factors that are currently influencing the Asthma Biologics market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.
Market Segmentation
Drug Class
- Selective Immuno-suppressants
- Interleukin Inhibitors
- Others
Distribution Channel
- Retail Pharmacies
- E-commerce
- Others
Region Segment (2022-2032; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Key questions answered in this report
What are the key micro and macro environmental factors that are impacting the growth of Asthma Biologics market?
What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2032.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Asthma Biologics market?
Which is the largest regional market for Asthma Biologics market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Asthma Biologics market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Asthma Biologics market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Asthma Biologics Market
- 2.2. Global Asthma Biologics Market, By Drug Class, 2023 (US$ Million)
- 2.3. Global Asthma Biologics Market, By Distribution Channel, 2023 (US$ Million)
- 2.4. Global Asthma Biologics Market, By Geography, 2023 (US$ Million)
- 2.5. Attractive Investment Proposition by Geography, 2023
3. Asthma Biologics Market: Competitive Analysis
- 3.1. Market Positioning of Key Asthma Biologics Market Vendors
- 3.2. Strategies Adopted by Asthma Biologics Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2023 Versus 2032
4. Asthma Biologics Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Asthma Biologics Market Value, 2022 - 2032, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
- 4.6. Porter's Five Force Model
- 4.6.1. Supplier Power
- 4.6.2. Buyer Power
- 4.6.3. Threat Of Substitutes
- 4.6.4. Threat Of New Entrants
- 4.6.5. Competitive Rivalry
- 4.7. PESTEL Analysis
- 4.7.1. Political Landscape
- 4.7.2. Economic Landscape
- 4.7.3. Technology Landscape
- 4.7.4. Legal Landscape
- 4.7.5. Social Landscape
5. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2023 Versus 2032
- 5.3. Market Segmentation
- 5.3.1. Selective Immuno-suppressants
- 5.3.2. Interleukin Inhibitors
- 5.3.3. Others
6. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2023 Versus 2032
- 6.3. Market Segmentation
- 6.3.1. Retail Pharmacies
- 6.3.2. E-commerce
- 6.3.3. Others
7. North America Asthma Biologics Market, 2022-2032, USD (Million)
- 7.1. Market Overview
- 7.2. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 7.3. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 7.4.Asthma Biologics Market: By Region, 2022-2032, USD (Million)
- 7.4.1.North America
- 7.4.1.1. U.S.
- 7.4.1.1.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 7.4.1.1.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 7.4.1.2. Canada
- 7.4.1.2.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 7.4.1.2.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 7.4.1.3. Rest of North America
- 7.4.1.3.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 7.4.1.3.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 7.4.1.1. U.S.
- 7.4.1.North America
8. UK and European Union Asthma Biologics Market, 2022-2032, USD (Million)
- 8.1. Market Overview
- 8.2. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 8.3. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.Asthma Biologics Market: By Region, 2022-2032, USD (Million)
- 8.4.1.UK and European Union
- 8.4.1.1. UK
- 8.4.1.1.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 8.4.1.1.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.1.2. Germany
- 8.4.1.2.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 8.4.1.2.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.1.3. Spain
- 8.4.1.3.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 8.4.1.3.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.1.4. Italy
- 8.4.1.4.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 8.4.1.4.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.1.5. France
- 8.4.1.5.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 8.4.1.5.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.1.6. Rest of Europe
- 8.4.1.6.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 8.4.1.6.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 8.4.1.1. UK
- 8.4.1.UK and European Union
9. Asia Pacific Asthma Biologics Market, 2022-2032, USD (Million)
- 9.1. Market Overview
- 9.2. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 9.3. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.Asthma Biologics Market: By Region, 2022-2032, USD (Million)
- 9.4.1.Asia Pacific
- 9.4.1.1. China
- 9.4.1.1.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 9.4.1.1.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.1.2. Japan
- 9.4.1.2.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 9.4.1.2.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.1.3. India
- 9.4.1.3.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 9.4.1.3.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.1.4. Australia
- 9.4.1.4.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 9.4.1.4.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.1.5. South Korea
- 9.4.1.5.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 9.4.1.5.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.1.6. Rest of Asia Pacific
- 9.4.1.6.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 9.4.1.6.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 9.4.1.1. China
- 9.4.1.Asia Pacific
10. Latin America Asthma Biologics Market, 2022-2032, USD (Million)
- 10.1. Market Overview
- 10.2. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 10.3. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.4.Asthma Biologics Market: By Region, 2022-2032, USD (Million)
- 10.4.1.Latin America
- 10.4.1.1. Brazil
- 10.4.1.1.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 10.4.1.1.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.4.1.2. Mexico
- 10.4.1.2.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 10.4.1.2.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.4.1.3. Rest of Latin America
- 10.4.1.3.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 10.4.1.3.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 10.4.1.1. Brazil
- 10.4.1.Latin America
11. Middle East and Africa Asthma Biologics Market, 2022-2032, USD (Million)
- 11.1. Market Overview
- 11.2. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 11.3. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.4.Asthma Biologics Market: By Region, 2022-2032, USD (Million)
- 11.4.1.Middle East and Africa
- 11.4.1.1. GCC
- 11.4.1.1.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 11.4.1.1.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.4.1.2. Africa
- 11.4.1.2.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 11.4.1.2.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.4.1.3. Rest of Middle East and Africa
- 11.4.1.3.1. Asthma Biologics Market: By Drug Class, 2022-2032, USD (Million)
- 11.4.1.3.2. Asthma Biologics Market: By Distribution Channel, 2022-2032, USD (Million)
- 11.4.1.1. GCC
- 11.4.1.Middle East and Africa
12. Company Profile
- 12.1. Amgen, Inc.
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Portfolio
- 12.1.4. Strategic Initiatives
- 12.2. AstraZeneca
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Portfolio
- 12.2.4. Strategic Initiatives
- 12.3. F. Hoffmann-La Roche Ltd.
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Portfolio
- 12.3.4. Strategic Initiatives
- 12.4. GSK plc
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Portfolio
- 12.4.4. Strategic Initiatives
- 12.5. Novartis AG
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Portfolio
- 12.5.4. Strategic Initiatives
- 12.6. Regeneron Pharmaceuticals, Inc.
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Portfolio
- 12.6.4. Strategic Initiatives
- 12.7. Sanofi
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Portfolio
- 12.7.4. Strategic Initiatives
- 12.8. Teva Pharmaceutical Industries Ltd.
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Portfolio
- 12.8.4. Strategic Initiatives
- 12.9. Other Prominent Players
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Portfolio
- 12.9.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 2 Global Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 3 North America Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 4 North America Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 5 U.S. Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 6 U.S. Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 7 Canada Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 8 Canada Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 9 Rest of North America Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 10 Rest of North America Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 11 UK and European Union Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 12 UK and European Union Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 13 UK Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 14 UK Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 15 Germany Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 16 Germany Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 17 Spain Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 18 Spain Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 19 Italy Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 20 Italy Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 21 France Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 22 France Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 23 Rest of Europe Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 24 Rest of Europe Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 25 Asia Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 26 Asia Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 27 China Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 28 China Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 29 Japan Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 30 Japan Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 31 India Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 32 India Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 33 Australia Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 34 Australia Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 35 South Korea Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 36 South Korea Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 37 Latin America Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 38 Latin America Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 39 Brazil Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 40 Brazil Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 41 Mexico Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 42 Mexico Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 43 Rest of Latin America Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 44 Rest of Latin America Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 45 Middle East and Africa Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 46 Middle East and Africa Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 47 GCC Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 48 GCC Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 49 Africa Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 50 Africa Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
- TABLE 51 Rest of Middle East and Africa Asthma Biologics Market By Drug Class, 2022-2032, USD (Million)
- TABLE 52 Rest of Middle East and Africa Asthma Biologics Market By Distribution Channel, 2022-2032, USD (Million)
List of Figures
- FIG. 1 Global Asthma Biologics Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Asthma Biologics Market: Quality Assurance
- FIG. 5 Global Asthma Biologics Market, By Drug Class, 2023
- FIG. 6 Global Asthma Biologics Market, By Distribution Channel, 2023
- FIG. 7 Global Asthma Biologics Market, By Geography, 2023
- FIG. 8 Market Geographical Opportunity Matrix - Global Asthma Biologics Market, 2023
FIG. 9Market Positioning of Key Asthma Biologics Market Players, 2023
FIG. 10Global Asthma Biologics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2023 Versus 2032
- FIG. 11 Global Asthma Biologics Market, By Drug Class, 2023 Vs 2032, %
- FIG. 12 Global Asthma Biologics Market, By Distribution Channel, 2023 Vs 2032, %
- FIG. 13 U.S. Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 14 Canada Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 15 Rest of North America Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 16 UK Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 17 Germany Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 18 Spain Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 19 Italy Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 20 France Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 21 Rest of Europe Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 22 China Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 23 Japan Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 24 India Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 25 Australia Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 26 South Korea Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 27 Rest of Asia Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 28 Brazil Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 29 Mexico Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 30 Rest of Latin America Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 31 GCC Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 32 Africa Asthma Biologics Market (US$ Million), 2022 - 2032
- FIG. 33 Rest of Middle East and Africa Asthma Biologics Market (US$ Million), 2022 - 2032
